Robert A Figlin Selected Research

PT2385

1/2020	HIF-2 Complex Dissociation, Target Inhibition, and Acquired Resistance with PT2385, a First-in-Class HIF-2 Inhibitor, in Patients with Clear Cell Renal Cell Carcinoma.
1/2018	Phase I Dose-Escalation Trial of PT2385, a First-in-Class Hypoxia-Inducible Factor-2α Antagonist in Patients With Previously Treated Advanced Clear Cell Renal Cell Carcinoma.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Robert A Figlin Research Topics

Disease

121	Renal Cell Carcinoma (Grawitz Tumor) 01/2020 - 09/2002
72	Neoplasms (Cancer) 01/2020 - 02/2003
17	Neoplasm Metastasis (Metastasis) 01/2020 - 02/2003
15	Kidney Neoplasms (Kidney Cancer) 05/2014 - 01/2003
9	Hypoxia (Hypoxemia) 01/2018 - 10/2003
8	Fatigue 01/2018 - 01/2007
8	Hypertension (High Blood Pressure) 01/2016 - 12/2003
7	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 09/2015 - 06/2006
6	Prostatic Neoplasms (Prostate Cancer) 12/2020 - 05/2004
5	Carcinoma (Carcinomatosis) 12/2005 - 02/2003
4	Disease Progression 01/2014 - 04/2006
3	Exanthema (Rash) 03/2010 - 08/2008
3	Carcinogenesis 11/2008 - 03/2005
2	Brain Neoplasms (Brain Tumor) 10/2019 - 03/2010
2	Colorectal Neoplasms (Colorectal Cancer) 12/2012 - 01/2008
2	Dyspnea (Shortness of Breath) 09/2010 - 10/2008
2	Lung Neoplasms (Lung Cancer) 07/2010 - 11/2008
2	Diarrhea 08/2009 - 01/2007
2	Hand-Foot Syndrome 08/2009 - 10/2008
2	Neutropenia 10/2008 - 11/2003
2	Cachexia 05/2004 - 11/2003
2	Thrombosis (Thrombus) 02/2004 - 03/2003
1	COVID-19 01/2020
1	Anemia 01/2018
1	Edema (Dropsy) 01/2018
1	Neuroendocrine Tumors (Neuroendocrine Tumor) 01/2017
1	Gastrointestinal Stromal Tumors (Gastrointestinal Stromal Tumor) 01/2017
1	Hyperglycemia 10/2016
1	Hypercholesterolemia 10/2016
1	Pancreatic Neoplasms (Pancreatic Cancer) 01/2016
1	Clear-cell metastatic renal cell carcinoma 01/2015

Drug/Important Bio-Agent (IBA)

23	Sunitinib (Sutent)FDA Link 01/2020 - 01/2006
16	Biomarkers (Surrogate Marker)IBA 01/2019 - 06/2004
14	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 10/2017 - 10/2003
14	TOR Serine-Threonine KinasesIBA 10/2016 - 10/2006
11	Proteins (Proteins, Gene)FDA Link 10/2014 - 05/2003
10	Interleukin-2 (IL2)IBA 02/2015 - 08/2003
10	Carbonic Anhydrase IXIBA 10/2014 - 02/2003
9	Interferon-alpha (Interferon Alfa)IBA 01/2014 - 01/2007
8	temsirolimus FDA Link 01/2013 - 11/2007
8	Biological ProductsIBA 08/2011 - 09/2002
7	InterferonsIBA 06/2014 - 09/2007
6	Tyrosine Kinase InhibitorsIBA 01/2019 - 01/2009
6	Vascular Endothelial Growth Factor Receptors (VEGF Receptors)IBA 01/2016 - 01/2006
6	VaccinesIBA 01/2015 - 01/2003
6	Sorafenib (BAY 43-9006)FDA Link 02/2014 - 08/2008
6	Bevacizumab (Avastin)FDA Link 09/2011 - 10/2007
5	Pharmaceutical PreparationsIBA 12/2015 - 10/2006
5	Erlotinib Hydrochloride (CP 358,774)FDA Link 09/2015 - 06/2006
5	AntigensIBA 07/2013 - 11/2003
5	MTOR InhibitorsIBA 12/2012 - 10/2006
5	CytokinesIBA 08/2012 - 08/2003
5	Monoclonal AntibodiesIBA 11/2010 - 03/2004
4	pazopanib FDA Link 12/2017 - 01/2010
4	Everolimus FDA Link 10/2016 - 08/2008
3	Docetaxel (Taxotere)FDA Link 12/2020 - 11/2003
3	RNA (Ribonucleic Acid)IBA 01/2020 - 07/2013
3	Hemoglobins (Hemoglobin)IBA 06/2017 - 05/2004
3	Celecoxib (Celebrex)FDA Link 09/2015 - 06/2006
3	Tumor Biomarkers (Tumor Markers)IBA 10/2014 - 09/2004
3	Phosphatidylinositols (Phosphatidylinositol)IBA 08/2013 - 08/2009
3	LigandsIBA 06/2008 - 10/2005
3	Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)IBA 11/2003 - 03/2003
2	AndrogensIBA 12/2020 - 01/2020
2	Androgen Receptors (Androgen Receptor)IBA 12/2020 - 01/2020
2	CD40 Ligand (CD40L)IBA 01/2020 - 01/2015
2	Transcription Factors (Transcription Factor)IBA 01/2020 - 01/2010
2	PT2385IBA 01/2020 - 01/2018
2	Angiogenesis InhibitorsIBA 01/2016 - 11/2013
2	Mechanistic Target of Rapamycin Complex 1IBA 08/2013 - 01/2013
2	Mechanistic Target of Rapamycin Complex 2IBA 08/2013 - 01/2013
2	Peptides (Polypeptides)IBA 07/2013 - 05/2004
2	Platelet-Derived Growth FactorIBA 01/2010 - 01/2006
2	Phosphatidylinositol 3-Kinase (1 Phosphatidylinositol 3 Kinase)IBA 12/2009 - 10/2006
2	ChemokinesIBA 06/2008 - 05/2007
2	Interleukin-4 (Interleukin 4)IBA 11/2003 - 03/2003
1	abirateroneIBA 12/2020
1	Anti-Bacterial Agents (Antibiotics)IBA 12/2019
1	Circulating Tumor DNAIBA 01/2019
1	Lactic Acid (Lactate)FDA LinkGeneric 06/2017
1	Imatinib Mesylate (Gleevec)FDA Link 01/2017
1	thiamine triphosphorate (TTP)IBA 01/2016
1	Vascular Endothelial Growth FactorsIBA 01/2016
1	Axitinib (AG 013736)IBA 12/2015
1	Dinoprostone (PGE2)FDA Link 09/2015
1	aldesleukin (Proleukin)FDA Link 02/2015
1	B7-H1 AntigenIBA 02/2015
1	Angiopoietin-2IBA 10/2014
1	Matrix Metalloproteinase 2 (Gelatinase A)IBA 10/2014
1	RamucirumabIBA 06/2014

Therapy/Procedure

65	Therapeutics 12/2020 - 12/2002
27	Nephrectomy 11/2016 - 09/2002
24	Immunotherapy 01/2020 - 09/2002
4	Drug Therapy (Chemotherapy) 10/2008 - 10/2003
2	Thrombectomy 02/2004 - 03/2003
1	Castration 12/2020
1	Duration of Therapy 10/2016
1	Precision Medicine 01/2016
1	Secondary Prevention 01/2015
1	Neoadjuvant Therapy 05/2014